Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
402 people get ARWR articles and Market Currents by email alert.
Get email alerts on ARWR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Arrowhead Research Subsidiary Granted China RNAi PatentChinaBio Today • Tue, May 20, 2008 -
Arrowhead Research Corporation: Bucky Balls Are BackDebra Fiakas • Tue, Sep 25, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
Undervalued Healthcare Sector Fund Manager PicksGuruFundPicks • Tue, Nov 15, 2011 -
-
Following the China Biopharma BeatChinaBio Today • Sun, May 25, 2008
-
-
The Wall Street Analyst Forum May Conference ScheduleThe Wall Street Analyst Forum • Fri, Apr 27, 2007
-
Arrowhead Research Corp. F1Q10 (Qtr End 12/31/09) Earnings Call TranscriptThu, Feb 11, 2010 • 1 Comment
-
Arrowhead Research Corp. F4Q09 (Qtr End 09/30/09) Earnings Call TranscriptTue, Dec 29, 2009 • 1 Comment
-
Arrowhead Research Corp. F3Q09 (Qtr End 30/06/09) Earnings Call TranscriptMon, Aug 10, 2009 • 1 Comment
-
Arrowhead Research Corporation Q1 2009 Earnings Call TranscriptMon, Feb 9, 2009
-
Business Wire (Thu, 4:30PM)
-
Business Wire (May 28, 2013)
-
Business Wire (May 13, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 1, 2013)
-
Business Wire (Jan 25, 2013)
-
Business Wire (Jan 24, 2013)
ARWR vs. ETF Alternatives
Company Description
Currently, there's no company description for ARWR.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Tuesday, April 30, 12:46 PM
Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move] - Monday, March 25, 9:10 AM Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%. Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%. Comment! [On the Move]
- Thursday, March 14, 9:25 AM Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating it can knock down hepatitis B virus DNA and key viral antigens. Comment! [Healthcare, On the Move]
-
Thursday, March 14, 9:15 AM
Premarket gainers: MW +15%. EBIX +14%. ARWR +8%. BLDP +6%. FTE +6%.
Losers: ANAD -8%. NBG -7%. DCTH -7%. ETFC -7%. VRA -6%. Comment! [On the Move] -
Tuesday, February 26, 9:10 AM
Premarket gainers: CWH +28%. ALC +22%. ARWR +17%. AXTI +8%. SPRD +7%. AUXL +6%. DCTH +5%.
Losers: TWI -10%. VVUS -7%. VSI -7%. EEQ -5%. 1 Comment [On the Move] - Friday, January 25, 1:39 PM Arrowhead Research (ARWR -7%) slides today after pricing its 1.65 million unit public offering at $2.12 per unit. Each unit consists of one share of common stock and one warrant to purchase 0.50 of a share of common. The company intends to use the net proceeds for general corporate purposes, including R&D and clinical trial expenditures, Comment! [On the Move]
-
Friday, January 25, 12:45 PM
Midday top 10 gainers: EFII +15%. OSK +15%. SHIP +15%. SYNA +15%. LSCC +14%. NFLX +14%. QLGC +13%. BDR +13%. CIMT +13%. CRUS +12%.
Midday top 10 Losers: NFBK -27%. ZN -26%. SCSS -18%. SCSC -15%. BGMD -15%. CTRP -13%. HTCH -11%. EGHT -10%. ARWR -8%. MSL -7%. Comment! [On the Move] - Friday, January 25, 8:06 AM Two other biotechs undertaking secondary offerings today: Arrowhead Research (ARWR) off 6.5% premarket - and Anthera Pharmaceuticals (ANTH) - off 10% premarket. (Arrowhead PR). (Anthera PR). (BG Medicine earlier). Comment! [Healthcare, On the Move]
- Tuesday, December 18, 2012, 12:17 PM Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement with Shire (SHPG +0.8%) to develop and commercialize targeted peptide-drug conjugates by utilizing ARWR's human-derived Homing Peptide platform and SHPG's therapeutic payloads. Arrowhead will receive research funding and could be eligible for milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, as well as royalties on worldwide sales. 2 Comments [Healthcare]
- Wednesday, October 31, 2012, 12:45 PM Midday top 10 gainers: SHF +46%. WRC +37%. OPNT +29%. RRGB +25%. MPAC +23%. RCON +23%. HNSN +20%. CVLT +20%. ARWR +20%. GPRE +19%. Midday top 10 Losers: IQNT -35%. OXF -31%. BCRX -29%. WU -28%. PBIB -25%. CRNT -24%. CHRM -20%. CBAK -18%. RVBD -19%. NBG -18%. 2 Comments [On the Move]
- Monday, August 13, 2012, 2:12 PM Shares of Arrowhead Research (ARWR -13.8%) hit a new 52-week low earlier in the session after the company says it's entered into a $6.2M securities purchase agreement with several institutional and individual investors, including James Mellon, and a new fund dedicated to health care investments. The placement consists of 2.3M shares of common stock, and warrants to purchase 1.7M shares, with each unit priced at $2.76 and consisting of one share of common stock and a warrant worth 0.75 shares. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Kudrna
Biotech: Archive - Arrowhead (ARWR) Acquires RNAi Assets From Roche http://bit.ly/ui5paz - View all 0 replies
-
Jim Van Meerten
ARWR - 80% Barchart technical buy signal - 18 new highs and up 53.85% in the last month - Relative strngth Index 70.73% and rising - View all 0 replies
-
- View all 0 replies
-
World Market Media
Arrowhead Research Corporation (NASDAQ: ARWR) $107M (MarketCap) Receives Grant from the State of Texas http://bit.ly/cpeyw9 - View all 0 replies
-
- View all 0 replies
LATEST REPLIES